Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.35 |
| ▸ | GPR6 | P46095 | 3/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | CCNT1 | O60563 | 10/20 | 0.33 |
| ▸ | CDK9 | P50750 | 10/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.32 |
| ▸ | POLQ | O75417 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21884500 | 0.93 | WDR5 (0.33) | RETGPR6WDR5GPBAR1CCNT1 | |
| SCHEMBL21884605 | 0.88 | CCNT1 (0.40) | CCNT1CDK9 | |
| SCHEMBL21884668 | 0.88 | GPR6 (0.32) | GPR6 | |
| SCHEMBL21884406 | 0.87 | WDR5 (0.44) | GPR6WDR5GPBAR1CCNT1CDK9 | |
| SCHEMBL21884570 | 0.86 | CCNT1 (0.34) | RETCCNT1CDK9ABL1POLQ | |
| SCHEMBL21884616 | 0.85 | WDR5 (0.40) | GPR6WDR5GPBAR1CCNT1CDK9 | |
| SCHEMBL21884359 | 0.84 | RIPK3 (0.32) | RETGPR6GPBAR1ABL1POLQ | |
| SCHEMBL21884564 | 0.84 | CSNK2A1 (0.34) | RETGPR6ABL1 | |
| SCHEMBL21884501 | 0.83 | CYP11B2 (0.35) | ABL1 | |
| SCHEMBL21884632 | 0.81 | CCNT1 (0.40) | CCNT1CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS INC. | 2021-12-02 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | JNANA THERAPEUTICS INC. | 2021-09-30 | — | — | US | disclosed |
| WO-2020061473-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | JNANA THERAPEUTICS, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299070-A1 | METHODS OF TREATING CREATINE TRANSPORTER DEFICIENCY | SLC19A1, SLC1A5, SLC1A2 | RET 1732/4885GPR6 1334/4885WDR5 3394/4885 |
| US-20210371403-A1 | SMALL MOLECULES TARGETING MUTANT MAMMALIAN PROTEINS | SNRPE, G3BP1, G3BP2 | RET 2969/4885GPR6 4070/4885WDR5 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.